The U.S. Drug Enforcement Administration has taken some cannabidiol off the most restrictive class of controlled substances, a move that allows the sale of the first nonsynthetic, cannabis-derived medicine to win federal approval.It's a decision that immediately affects CBD producers but also signals the agency's first admission that the plant has medical value.Read full news